Related Experiment Video
Updated: Feb 5, 2026
13:24
Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies
Published on: April 11, 2016
12.3K
TIGIT: a novel immunotherapy target moving from bench to bedside
Benjamin L Solomon1, Ignacio Garrido-Laguna2,3
1Oncology Division, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah School of Medicine, 2000 Circle of Hope, Suite 2100, Salt Lake City, UT, 84112, USA. Benjamin.solomon@hci.utah.edu.
Cancer Immunology, Immunotherapy : CII
|September 21, 2018
Summary
Immunotherapy shows promise for cancer treatment but often fails in "cold tumors." Targeting the TIGIT immune checkpoint may overcome this resistance, potentially enhancing existing cancer immunotherapies.
Area of Science:
- Immunology
- Oncology
- Cancer Immunotherapy
Background:
- Advanced solid tumors are challenging to treat with current modalities like surgery, chemotherapy, and targeted therapies.
- Cancer immunotherapy has emerged as a novel treatment paradigm, but response rates remain limited, particularly in patients with "cold tumors."
- Cold tumors are characterized by an immunosuppressive tumor microenvironment, low T cell infiltration, and reduced mutational and neoantigen burden.
Purpose of the Study:
- To explore the role of the TIGIT (T cell immunoreceptor with Ig and ITIM domains) immune checkpoint in tumor immunosurveillance.
- To investigate the potential of targeting TIGIT as a strategy to overcome immunotherapy resistance in solid tumors.
- To evaluate the synergistic potential of anti-TIGIT antibodies with existing immunotherapies like anti-PD-1/PD-L1 antibodies.
Main Methods:
- Review of scientific literature on TIGIT function, expression in cancer, and its interaction with other immune checkpoints.
- Analysis of pre-clinical models investigating the efficacy of anti-TIGIT antibodies.
- Examination of ongoing clinical trials evaluating anti-TIGIT therapies.
Main Results:
- TIGIT is an inhibitory immune checkpoint expressed on T cells and NK cells, playing a role in immune suppression.
- TIGIT competes with the activating receptor CD226 for ligands CD155 and CD112, contributing to tumor immune evasion.
- Pre-clinical studies demonstrate that anti-TIGIT antibodies can synergize with anti-PD-1/PD-L1 antibodies, enhancing anti-tumor immunity.
Conclusions:
- TIGIT represents a promising therapeutic target for enhancing cancer immunotherapy efficacy, especially in patients unresponsive to current treatments.
- Combination strategies involving anti-TIGIT and anti-PD-1/PD-L1 antibodies hold potential for improving outcomes in advanced solid tumors.
- Ongoing clinical trials are crucial for validating the therapeutic benefit of targeting the TIGIT pathway in cancer patients.
Related Concept Videos
01:27Tumor Immunotherapy
1.9K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.9K
01:23Magnetic Field due to Moving Charges
11.7K
A stationary charge creates and interacts with the electric field, while a moving charge creates a magnetic field.
Consider a point charge moving with a constant velocity. Like the electric field, the magnetic field at any point is directly proportional to the magnitude of the charge and inversely proportional to the square of the distance between the source point and the field point. However, unlike the electric field, the magnetic field is always perpendicular to the plane containing the line...
Consider a point charge moving with a constant velocity. Like the electric field, the magnetic field at any point is directly proportional to the magnitude of the charge and inversely proportional to the square of the distance between the source point and the field point. However, unlike the electric field, the magnetic field is always perpendicular to the plane containing the line...
11.7K
01:14Conservation of Mass in Moving, Nondeforming Control Volume
1.3K
Stormwater detention basins are essential in managing runoff during heavy rainfall, particularly in urban areas where impervious surfaces increase the risk of flooding. Understanding the conservation of mass in these systems allows engineers to optimize basin performance, balancing inflow, outflow, and water storage.
In the context of a detention basin, the conservation of mass states that the total mass of water entering the basin must equal the mass leaving the basin plus any accumulation of...
In the context of a detention basin, the conservation of mass states that the total mass of water entering the basin must equal the mass leaving the basin plus any accumulation of...
1.3K
02:57Targeted Cancer Therapies
8.9K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.9K
01:26Targets for Drug Action: Overview
10.3K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
10.3K
01:22Target Cell Response to Hormones
5.8K
Hormones intricately bind to receptors on the surface or within target cells, initiating a cascade of cellular responses.
Notably, the cellular response can be regulated by altering the number of receptors expressed in the cell. For example, prolonged exposure to elevated hormone levels results in a gradual decline or down-regulation in the number of receptors for that specific hormone on the cell surface. Conversely, in response to low hormone levels, cells may use up-regulation, producing an...
Notably, the cellular response can be regulated by altering the number of receptors expressed in the cell. For example, prolonged exposure to elevated hormone levels results in a gradual decline or down-regulation in the number of receptors for that specific hormone on the cell surface. Conversely, in response to low hormone levels, cells may use up-regulation, producing an...
5.8K